Adacel

BIOLOGICAL4 trials

Sponsors

GlaxoSmithKline, Mahidol University, GCAM Inc.

Conditions

Acellular PertussisDiphtheriaPertussisTetanus

Phase 2

Tdap Vaccine Safety for Plasma Donors

CompletedNCT04142983

GCAM Inc.Tetanus

Start: 2020-02-03End: 2021-11-16Updated: 2022-12-06

Phase 3

Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9

CompletedNCT00489970

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Tetanus

Start: 2007-06-01End: 2016-03-01Updated: 2020-05-01

Unknown Phase

3-year Follow-up After a Single Dose Acellular Pertussis Vaccination

CompletedNCT04102137

Mahidol UniversityPertussis

Start: 2018-06-26End: 2018-08-27Updated: 2019-10-01

2-year Follow-up After a Single Dose Acellular Pertussis Vaccination

CompletedNCT04113655

Mahidol UniversityPertussis

Start: 2017-06-20End: 2017-07-31Updated: 2019-10-03

Related Papers

Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.

2018-09-0710 citations